The Program in Cancer Immunology and Immunotherapy is focused on understanding the interactions between the host immune system and tumors, and on the discovery and development of clinically effective anti-tumor immunotherapy. The program comprises faculty members whose academic interests are in molecular and cellular immunobiology, medicine, surgery, psychiatry and pathology in the Stanford University School of Medicine. Each faculty member has his or her own independent research program and also works collaboratively with members of both this program and other Cancer Center programs. In addition, each faculty member is active in teaching graduate and medical students, as well as training postdoctoral fellows and residents. These shared responsibilities, along with regular journal clubs, program project review meetings and an annual immunology retreat, help to foster interactions between faculty members in the program. Three complementary approaches are being taken to achieve the three goals of our program: ? To develop new and more precise ways of measuring and monitoring the immune response to tumors in tumor-bearing hosts. ? To develop an understanding of the biochemical and signaling pathways used by T cells and other immune effector cells in both their response to tumors and their cellular trafficking patterns. ? To manipulate cells of the immune system in patients with solid tumors with the goal of utihzing the exquisite specificity of this system to achieve tumor eradication without significant toxicity. Understanding and manipulating the immune response to tumors, particularly solid tumors, is the major unifying research interest of the participants in this Research Program, and our ability to achieve our objectives is highly dependent on both basic and translational investigators from the other Programs in the Cancer Center and on the Shared Resources.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
United States
Zip Code
Ganjoo, Kristen; Hong, Fangxin; Horning, Sandra J et al. (2014) Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma 55:768-72
Chiou, Shin-Heng; Kim-Kiselak, Caroline; Risca, Viviana I et al. (2014) A conditional system to specifically link disruption of protein-coding function with reporter expression in mice. Cell Rep 7:2078-86
Zhu, Gefei Alex; Danial, Christina; Liu, Andy et al. (2014) Overall and progression-free survival in metastatic basosquamous cancer: a case series. J Am Acad Dermatol 70:1145-6
Caswell, Deborah R; Chuang, Chen-Hua; Yang, Dian et al. (2014) Obligate progression precedes lung adenocarcinoma dissemination. Cancer Discov 4:781-9
Bartroff, Jay; Lai, Tze Leung; Narasimhan, Balasubramanian (2014) A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies. Stat Med 33:2718-35
Kohrt, Holbrook E; Thielens, Ariane; Marabelle, Aurelien et al. (2014) Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123:678-86
DiCarlo, Joseph; Agarwal-Hashmi, Rajni; Shah, Ami et al. (2014) Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant 20:361-9
Chang, Serena; Kohrt, Holbrook; Maecker, Holden T (2014) Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother 63:713-9
Ansari, Celina; Tikhomirov, Grigory A; Hong, Su Hyun et al. (2014) Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. Small 10:566-75, 417
Lavori, Philip W; Dawson, Ree (2014) Introduction to dynamic treatment strategies and sequential multiple assignment randomization. Clin Trials 11:393-399

Showing the most recent 10 out of 24 publications